±±¾©Ê¯ÓÍ»¯¹¤Ñ§Ôº2026ÄêÑо¿ÉúÕÐÉú½ÓÊÕµ÷¼Á¹«¸æ
²é¿´: 286  |  »Ø¸´: 3
µ±Ç°Ö÷ÌâÒѾ­´æµµ¡£

2110907077

½ð³æ (³õÈëÎÄ̳)

[½»Á÷] °ï°ï棬лл£¡

Bacterial resistance development has become a very serious clinical problem for many classes of antibiotics. The 3-aryl-2-oxazolidinones are a relatively new class of synthetic antibacterial agents, having a new mechanism of action which involves very early inhibition of bacterial protein synthesis. We have prepared two potent, synthetic oxazolidinones, U-100592 and U-100766, which are currently in clinical development for the treatment of serious multidrug-resistant Gram-positive bacterial infections caused by strains of staphylococci, streptococci,and enterococci. The in vitro and in vivo (po and iv) activities of U-100592 and U-100766 against representative strains are similar to those of vancomycin. U-100592 and U-100766 demonstrate potent in vitro activity against Mycobacterium tuberculosis. A novel and practical asymmetric synthesis of (5S)-(acetamidomethyl)-2-oxazolidinones has been developed and is employed for the synthesis of U-100592 and U-100766. This involves the reaction of N-lithioarylcarbamates with (R)-glycidyl butyrate, resulting in excellent yields and high
enantiomeric purity of the intermediate (R)-5-(hydroxymethyl)-2-oxazolidinones.

» ²ÂÄãϲ»¶

ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

syh9288

¾èÖú¹ó±ö (ÖøÃûдÊÖ)

º£¾üÉϽ«

¡ï ¡ï ¡ï ¡ï ¡ï ¡ï
zap65535(½ð±Ò+6,VIP+0):²¹·¢ 12-25 01:14
¶ÔÓÚÐí¶àÖÖ¿¹ÉúËØÀ´Ëµ£¬Ï¸¾úµÄ¿¹ÐÔÔöÇ¿ÒѳÉΪһ¸ö·Ç³£ÑÏÖØµÄÁÙ´²ÎÊÌâ¡£3-·¼»ù-2-¶ñßòÍé¶þͪÊǺϳɵÄÐÂÐÍ¿¹¾úÎËüÓÐ×ÅȫеÄ×÷ÓûúÖÆ£º½ÏÔçµØÒÖÖÆÏ¸¾úÌåÄÚµ°°×Öʵĺϳɡ£ÎÒÃÇÖÆ±¸ÁËÁ½Öֺϳɵõ½¡¢ÓÐҩЧµÄßòÍéͪÀ໯ºÏÎïU-100592ºÍU-100766,ĿǰÕý´¦ÓÚÁÙ´²¿ª·¢½×¶Î£¬ÓÃÓÚÖÎÁÆÒòÆÏÌÑÇò¾ú¾úÖê¡¢Á´Çò¾ú¾úÖêºÍ³¦Çò¾úÒýÆðµÄ¡¢ÑÏÖØµÄ¡¢¶Ô¶àÖÖÒ©Îï¶¼¾ßÓп¹ÐԵĸïÀ¼ÊÏÑôϸ¾úµÄ¸ÐȾ¡£ÎÞÂÛÊÇÔÚÌåÄÚ»¹ÊÇÔÚÌåÍ⣬U-100592 U-100766ÕâÁ½ÖÖ»¯ºÏÎï¶ÔÓÚµäÐ͵ľúÖêµÄ×÷Óùý³ÌÓëÍò¹ÅÃ¹ËØµÄºÜÏàËÆ¡£ÔÚÌåÍâʵÑéÖÐU-100592ºÍU-100766±íÏÖ³ö¶Ô·Î½áºË¸Ë¾úÓÐןÜÇ¿µÄЧ¹û¡£ÎÒÃÇ·¢ÏÖÁËÒ»ÖÖÐÂӱʵÓõÄ5S-ÒÒõ£°±°±¼×»ù-2-ßòÍé¶þͪ²»¶Ô³ÆºÏ³É·¨£¨5S-acetamidomethyl-2-oxazolidinones£©²¢Í¨¹ý´Ë·¨ºÏ³ÉÁËU-100592ºÍU-100766¡£ÕâÉæ¼°lithioarylcarbamatesÓë»·Ñõ±û»ù¶¡ËáÑεķ´Ó¦£¬Í¨¹ý´Ë·´Ó¦ÎÒÃÇÄܵõ½ºÜ¸ßµÄ²úÁ¿ºÍÖмäÌå(R)-2-ôǼ׻ù-2-¶ñßò¶þͪµÄ¸ß´¿¶È¶ÔÓ³Ìå¡£
ÈËÉúÈçÃΣ¬Ò»é×»¹õª½­ÔÂ
2Â¥2009-12-18 22:18:24
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

lingbaobei

zap65535(½ð±Ò+0,VIP+0):ÖÊÁ¿²»ºÏ¸ñ 12-25 01:14
¶ÔÐí¶à¿¹¾úѧÀ´½²£¬¿¹¾úÒ©Æ·µÄ¿ª·¢ÊǺÜÖØÒªµÄÁÙ´²ÎÊÌâ¡£The 3-aryl-2-oxazolidinones ÊÇÏà¶Ô½ÏÐÂÖÖÀàµÄºÏ³É¿¹¾ú¼Á£¬ËüµÄÐÂ×÷ÓûúÀí°üÀ¨ÔÚÔçÆÚ×èÖ¹²¡¾úµ°°×ÖÊµÄºÏ³É .ÎÒÃÇ×¼±¸ÁË2ÖÖÓÐЧµÄÈ˹¤ºÏ³É¼Áoxazolidinones, U-100592 ºÍ U-100766£¬ËüÃÇÊÇÏÖ½ñÁÙ´²·¢Õ¹ÉÏÕë¶ÔÓÉÆÏÌÑÌǾú¡¢Á´Çò¾úºÍ³¦Çò¾úÒýÆðµÄÑÏÖØµÄ¶àÖØÄÍÒ©ÐÔ¸ïÀ¼ÊÏ(Ⱦɫ)ÑôÐÔϸ¾ú¸ÐȾµÄÖÎÁÆÒ©Æ·¡£The in vitro and in vivo (po and iv) activities of U-100592 and U-100766 against representative strains are similar to those of vancomycin. ÔÚ¶Ô¿¹µäÐ͵ļ²²¡ÀàÐÍÖУ¬U-100592 ºÍU-100766 ÔÚÊÔ¹ÜÖкÍÓлúÌåÄڵĻîÔ¾ÐÔºÍÍò¹ÅÃ¹ËØÏàËÆ
3Â¥2009-12-18 23:24:39
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

15890734984

ľ³æ (СÓÐÃûÆø)

telomerase(½ð±Ò+0,VIP+0):»úÒëÇë˵Ã÷£¬·ñÔòÑϳͣ¡£¡£¡ 12-19 18:31
ÄÍÒ©µÄ·¢Õ¹ÒѳÉΪһ¸ö·Ç³£ÑÏÖØµÄÎÊÌâ,Ðí¶àÀ࿹ÉúËØ¡£Õâ¸ö3-aryl-2-oxazolidinonesÊǸöÐÂÉú°àµÄ¿¹¾úÒ©ÎïºÏ³É¡¢ÐÂÐ͵Ä×÷ÓûúÖÆÉæ¼°·Ç³£ÔçÆÚµÄÒÖÖÆÏ¸¾úµ°°×Öʵĺϳɡ£ÎÒÃÇ×¼±¸ÁËÁ½¸öÇ¿ÓÐÁ¦µÄ¡¢ºÏ³Éoxazolidinones,U-100592ºÍU-100766,ĿǰÕý´¦ÓÚÁÙ´²¿ª·¢ÓÃÓÚÖÎÁÆÑÏÖØµÄ̵Һ¸ïÀ¼ÊÏÑôÐÔ¾ú¾úÖêÒýÆðµÄ¸ÐȾÁ´Çò¾úºÍÆÏÌÑÇò¾ú,enterococci¡£ÔÚÌåÍâºÍÌåÄÚ(po,(ËÄ)»î¶¯,¶Ô¾ßÓдú±íÐԵľúÖêU-100592 U-100766ÏàËÆµÄÍò¹ÅÃ¹ËØ¡£U-100592ºÍU-100766Õ¹ÏÖÔÚÌåÍâʵÑéÖжԷνáºË¡£Ò»¸öÐÂӱʵÓõIJ»¶Ô³ÆºÏ³É(5S)-(acetamidomethyl·´Ó¦ÒÑ¿ª·¢ºÍÊܹ͵ĺϳÉU-100592ºÍU-100766¡£ÕâÉæ¼°µ½µÄ·´Ó¦Óë(R)-glycidyl N-lithioarylcarbamates¶¡Ëá¡¢µ¼ÖÂÓÅÐãµÄ²úÁ¿ºÍ¸ß
¡¡¡¡¶ÔÓ³Ìå´¿¶ÈµÄÖмä(R)- 5 -(ÏȽ«·´Ó¦¡£
4Â¥2009-12-19 13:43:42
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
Ïà¹Ø°æ¿éÌø×ª ÎÒÒª¶©ÔÄÂ¥Ö÷ 2110907077 µÄÖ÷Ìâ¸üÐÂ
×î¾ßÈËÆøÈÈÌûÍÆ¼ö [²é¿´È«²¿] ×÷Õß »Ø/¿´ ×îºó·¢±í
[¿¼ÑÐ] µ÷¼Á +6 19945159693 2026-04-03 7/350 2026-04-03 22:04 by à£à£à£0119
[¿¼ÑÐ] Ò»Ö¾Ô¸ÖØÇì´óѧ085404£¬×Ü·Ö314·Ö£¬Çóµ÷¼Á +4 zf83hn 2026-04-03 4/200 2026-04-03 21:25 by à£à£à£0119
[¿¼ÑÐ] 0856£¬269·ÖÇóµ÷¼Á +15 ÓÐѧÉϾÍÐÐÇóÇóÁ 2026-03-30 18/900 2026-04-03 16:50 by melodiousnow
[¿¼ÑÐ] ¹¤¿Æ341·Öµ÷¼Á +3 Âå¶àÂÞ 2026-04-03 3/150 2026-04-03 14:20 by 1753564080
[˶²©¼ÒÔ°] ÇóÀÏʦÊÕÁô +9 lllq123 2026-04-03 9/450 2026-04-03 13:48 by ºôÎü¶¼ÊǼõ·Ê
[¿¼ÑÐ] ¡£ +4 ÎíÓ뺣 2026-04-02 5/250 2026-04-02 19:16 by ÍÁľ˶ʿÕÐÉú
[¿¼ÑÐ] 348Çóµ÷¼Á +11 zzzzyk123 2026-04-01 11/550 2026-04-02 16:52 by Wang200018
[¿¼ÑÐ] Ò»Ö¾Ô¸ÉϺ£º£Ñó´óѧ083200ʳƷѧ˶£¬Çóµ÷¼Á£¬½ÓÊÜÆäËûרҵ +6 whatÕÅ 2026-04-01 7/350 2026-04-02 16:48 by zzsw+
[¿¼ÑÐ] 285Çóµ÷¼Á +14 AZMK 2026-04-02 14/700 2026-04-02 15:54 by ÉϾÅÌìÀ¿Ô£¨ºÃÔ
[¿¼ÑÐ] Ò»Ö¾Ô¸Ö£´ó²ÄÁϹ¤³Ì290Çóµ÷¼Á +20 Youth_ 2026-03-30 20/1000 2026-04-02 14:48 by 5896
[¿¼ÑÐ] Ò»Ö¾Ô¸±±¾©¿Æ¼¼´óѧ085601²ÄÁϹ¤³ÌÓ¢Ò»Êý¶þ³õÊÔ×Ü·Ö335Çóµ÷¼Á +8 Ë«ÂíβƦÀϰå2 2026-04-02 9/450 2026-04-02 14:45 by 5896
[¿¼ÑÐ] ѧ˶»¯Ñ§¹¤³ÌÓë¼¼Êõ£¬Ò»Ö¾Ô¸Öйúº£Ñó´óѧ320+Çóµ÷¼Á +8 ÅûÐÇºÓ 2026-04-02 8/400 2026-04-02 14:12 by oooqiao
[¿¼ÑÐ] 0710ÉúÎïѧÇóµ÷¼Á +9 manman511 2026-04-01 9/450 2026-04-02 10:00 by zxl830724
[¿¼ÑÐ] 085601²ÄÁϹ¤³ÌÕÒµ÷¼Á +20 oatmealR 2026-03-29 21/1050 2026-04-01 21:00 by lijunpoly
[¿¼ÑÐ] µ÷¼Á +5 ºÃºÃ¶ÁÊé¡£ 2026-03-28 7/350 2026-04-01 15:32 by ÍõÁÁ_´óÁ¬Ò½¿Æ´ó
[¿¼ÑÐ] 08¹¤¿Æ£¬295£¬½ÓÊÜ¿çרҵµ÷¼Á +6 lmnlzy 2026-03-31 6/300 2026-04-01 11:02 by ÄæË®³Ë·ç
[¿¼ÑÐ] 0710ÉúÎïѧÇóµ÷¼Á£¡ +6 ÐðÊöÎÄ 2026-03-31 6/300 2026-04-01 09:39 by JourneyLucky
[¿¼ÑÐ] Ò»Ö¾Ô¸Î÷½»´ó080500²ÄÁÏѧ˶349 +6 jqx1258 2026-03-31 7/350 2026-03-31 21:08 by yuq
[¿¼ÑÐ] Ò»Ö¾Ô¸´óÁ¬Àí¹¤´óѧ£¬»úе¹¤³Ìѧ˶£¬341 +3 Î÷¹ÏÌïµÄÊØÍûÕß 2026-03-30 3/150 2026-03-31 11:08 by asdfzly
[¿¼ÑÐ] Ò»Ö¾Ô¸Öк£Ñó320»¯Ñ§¹¤³ÌÓë¼¼Êõѧ˶Çóµ÷¼Á +8 ÅûÐÇºÓ 2026-03-30 8/400 2026-03-31 08:53 by lbsjt
ÐÅÏ¢Ìáʾ
ÇëÌî´¦ÀíÒâ¼û